Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250 cm2 on the Chest

Trial Profile

Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250 cm2 on the Chest

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Apr 2017

At a glance

  • Drugs Ingenol mebutate (Primary)
  • Indications Actinic keratosis
  • Focus Registrational; Therapeutic Use
  • Sponsors LEO Pharma
  • Most Recent Events

    • 15 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 23 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 02 Mar 2016 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top